Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.

Second Quarter 2014 Financial Results

Genmab reported its Second Quarter 2014 financial results and held an investor conference call on August 13. Click the following links to access the archived call: listen to the webcastdownload the podcast; download the slide presentation.

Envisioning the Future of Cancer Treatment: A Video with CEO Jan van de Winkel

Genmab's CEO shares his perspective on how the company's work to develop innovative antibody therapeutics could change the lives of cancer patients in the future.  Click here to watch the video.

Genmab Opens Doors to Innovation

Genmab is inviting researchers in academia and industry to experience the full power of the DuoBody® platform for bispecific antibody research and drug development. Explore the possibilities via our recently published Perspective in the journal mAbs and the renewed Open Innovation section on

Latest news


  • At the heart of Genmab is a deep desire to improve the quality of life for cancer patients.
  • Click here to watch our video about our fight against cancer.


Stock Price as of 09/16/2014 11:20 AM (CET)

  • Share Price DKK 232.30
  • Change (in DKK) -2.80
  • Volume 33770

Stock Information